Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 16/20 | 0.56 |
| ▸ | SLC5A1 | P13866 | 12/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1729084 | 0.93 | SLC5A2 (0.59) | SLC5A2SLC5A1EPHX2POLB | |
| SCHEMBL13764484 | 0.90 | SLC5A2 (0.70) | SLC5A2SLC5A1 | |
| SCHEMBL1727955 | 0.89 | SLC28A3 (0.52) | SLC5A2SLC5A1EPHX2 | |
| SCHEMBL1728347 | 0.89 | SLC5A1 (0.54) | SLC5A2SLC5A1EPHX2 | |
| SCHEMBL13764485 | 0.87 | SLC5A2 (0.58) | SLC5A2SLC5A1POLB | |
| SCHEMBL1728291 | 0.86 | SLC5A2 (0.56) | SLC5A2SLC5A1 | |
| SCHEMBL1726690 | 0.86 | SLC5A2 (0.56) | SLC5A2SLC5A1 | |
| SCHEMBL1728404 | 0.83 | SLC5A2 (0.53) | SLC5A2SLC5A1EPHX2 | |
| SCHEMBL1728250 | 0.83 | SLC5A2 (0.60) | SLC5A2SLC5A1 | |
| SCHEMBL1728107 | 0.81 | SLC5A2 (0.53) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140212473-A1 | GLYCOPEPTIDE AND USES THEREOF | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-7566699-B2 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-7566699-B2 | Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140212473-A1 | GLYCOPEPTIDE AND USES THEREOF | LGALS3BP, SIGLEC7, LNPEP | SLC5A2 834/4885SLC5A1 984/4885EPHX2 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.